Claims for Patent: 9,238,053

Summary for Patent: 9,238,053

Title:	Methods for treatment of pain
Abstract:	The invention provides for methods and compositions for treatment of pain via craniofacial mucosal administration of an analgesic compound (e.g. a non-opioid analgesic peptide, an NOP agonist or N/OFQ). Intranasal administration of certain analgesic peptides such as N/OFQ results in global analgesic effects.
Inventor(s):	Toll; Lawrence R. (Redwood City, CA), Yeomans; David C. (Sunnyvale, CA), Angst; Martin S. (Palo Alto, CA), Jacobs; Daniel I. (Mountain View, CA)
Assignee:	Nocicepta LLC (Wilmington, DE)
Application Number:	13/802,075
Patent Claims:	1. A method for the treatment of pain comprising administering to an individual in need thereof an effective dose of a non-opioid peptide NOP agonist via intranasal administration, provided when the pain is a trigeminal nerve-associated pain, the non-opioid peptide NOP agonist is not co-administered with an oxytocin peptide. 2. The method of claim 1, wherein said treatment comprises treatment of a trigeminal pain, a somatic pain, a neuropathic pain or a visceral pain. 3. The method of claim 2, wherein said treatment comprises treatment of a somatic pain. 4. The method of claim 2, wherein said treatment comprises treatment of a neuropathic pain. 5. The method of claim 2, wherein said treatment comprises treatment of a visceral pain. 6. The method of claim 1, wherein said treatment comprises treatment of an acute pain or a chronic pain. 7. The method of claim 1, wherein the pain is a craniofacial pain or a head pain. 8. The method of claim 7, wherein the craniofacial pain or the head pain is caused by temporomandibular joint disorder (TMJ), migraine or trigeminal neuralgia. 9. The method of claim 8, wherein the craniofacial pain or the head pain is caused by temporomandibular joint disorder (TMJ). 10. The method of claim 8, wherein the craniofacial pain or the head pain is caused by migraine. 11. The method of claim 8, wherein the craniofacial pain or the head pain is caused by trigeminal neuralgia. 12. The method of claim 1, wherein said treatment comprises treatment of a somatic pain, a neuropathic pain or a visceral pain. 13. The method of claim 12, wherein the non-opioid peptide NOP agonist is not co-administered with an oxytocin peptide. 14. The method of claim 1, wherein the non-opioid peptide NOP agonist is selected from the group consisting of N/OFQ, truncated N/OFQ analogs, N/OFQ agonist peptides and NOP agonist hexapeptides. 15. The method of claim 14, wherein the non-opioid peptide NOP agonist is a truncated N/OFQ analog. 16. The method of claim 1, further comprising administering to the individual in need thereof at least one additional active agent, wherein the additional active agent is administered before, after or simultaneously with administration of the non-opioid peptide NOP agonist. 17. The method of claim 16, wherein the additional active agent is selected from the group consisting of non-peptide opioids, opioid and opioid-like peptides and their analogs, NMDA-receptor antagonists, sodium channel blockers, calcium channel blockers, adrenergic antagonists, gabaergic agonists, glycine agonists, cholinergic agonists, adrenergic agonists, epinephrine, anticonvulsants, Rho kinase inhibitors, PKC inhibitors, p38-MAP kinase inhibitors, ATP receptor blockers, endothelin receptor blockers, chemokines, interleukin and tumor necrosis factor blockers, pro-inflammatory cytokines, tricyclic antidepressants, serotonergic antagonists, serotonergic agonists, NSAIDs and COXIBs, acetaminophen, analgesic peptides, toxins, TRP channel agonists and antagonists, cannabanoids, antagonists of pro-nociceptive peptide neurotransmitter receptors CGRP1 and CGRP2, antagonists of pro-nociceptive peptide neurotransmitter receptor NK1, antagonists of pro-nociceptive peptide neurotransmitter receptor NK2, antagonists of pro-nociceptive peptide neurotransmitter receptor Y1-5, antagonists of pro-nociceptive peptide neurotransmitter receptors VPAC2, VPAC1 or PAC1, antagonists of pro-nociceptive peptide neurotransmitter receptors Gal1-3 or GalR1-3, agonists or antagonists of vasopressin, corticotropin releasing hormone (CRH), growth hormone releasing hormone (GHRH), luteinizing hormone releasing hormone (LHRH), somatostatin growth hormone release inhibiting hormone, thyrotropin releasing hormone (TRH), glial-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), neurotrophin-3 (NT-3), pancreatic polypeptide, peptide tyrosine-tyrosine, glucogen-like peptide-1 (GLP-1), peptide histidine isoleucine (PHI), pituitary adenylate cyclase activating peptide (PACAP), brain natriuretic peptide, cholecystokinin (CCK), islet amyloid polypeptide (IAPP) or amylin, melanin concentrating hormone (MCH), melanocortins (ACTH, .alpha.-MSH and others), neuropeptide FF (F8Fa), neurotensin, parathyroid hormone related protein, calcitonin, Agouti gene-related protein (AGRP), cocaine and amphetamine regulated transcript (CART)/peptide, 5-HT-moduline, hypocretins/orexins, nocistatin, prolactin releasing peptide, secretoneurin, urocortin and derivatives and analogues thereof. 18. The method of claim 1, wherein the non-opioid peptide NOP agonist is administered as a pharmaceutical composition. 19. The method of claim 18, wherein the pharmaceutical composition further comprises at least one additional active agent. 20. The method of claim 18, wherein the pharmaceutical composition further comprises one or more additional active agents selected from the group consisting of non-peptide opioids, opioid and opioid-like peptides and their analogs, NMDA-receptor antagonists, sodium channel blockers, calcium channel blockers, adrenergic antagonists, gabaergic agonists, glycine agonists, cholinergic agonists, adrenergic agonists, epinephrine, anticonvulsants, Rho kinase inhibitors, PKC inhibitors, p38-MAP kinase inhibitors, ATP receptor blockers, endothelin receptor blockers, chemokines, interleukin and tumor necrosis factor blockers, pro-inflammatory cytokines, tricyclic antidepressants, serotonergic antagonists, serotonergic agonists, NSAIDs and COXIBs, acetaminophen, analgesic peptides, toxins, TRP channel agonists and antagonists, cannabanoids, antagonists of pro-nociceptive peptide neurotransmitter receptors CGRP1 and CGRP2, antagonists of pro-nociceptive peptide neurotransmitter receptor NK1, antagonists of pro-nociceptive peptide neurotransmitter receptor NK2, antagonists of pro-nociceptive peptide neurotransmitter receptor Y1-5, antagonists of pro-nociceptive peptide neurotransmitter receptors VPAC2, VPAC1 or PAC1, antagonists of pro-nociceptive peptide neurotransmitter receptors Gal1-3 or GalR1-3, agonists or antagonists of vasopressin, corticotropin releasing hormone (CRH), growth hormone releasing hormone (GHRH), luteinizing hormone releasing hormone (LHRH), somatostatin growth hormone release inhibiting hormone, thyrotropin releasing hormone (TRH), glial-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), neurotrophin-3 (NT-3), pancreatic polypeptide, peptide tyrosine-tyrosine, glucogen-like peptide-1 (GLP-1), peptide histidine isoleucine (PHI), pituitary adenylate cyclase activating peptide (PACAP), brain natriuretic peptide, cholecystokinin (CCK), islet amyloid polypeptide (IAPP) or amylin, melanin concentrating hormone (MCH), melanocortins (ACTH, .alpha.-MSH and others), neuropeptide FF (F8Fa), neurotensin, parathyroid hormone related protein, calcitonin, Agouti gene-related protein (AGRP), cocaine and amphetamine regulated transcript (CART)/peptide, 5-HT-moduline, hypocretins/orexins, nocistatin, prolactin releasing peptide, secretoneurin, urocortin and derivatives and analogues thereof. 21. The method of claim 18, wherein the pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients, adjuvants, diluents or stabilizers. 22. The method of claim 18, wherein the pharmaceutical composition further comprises at least one protease inhibitor and/or at least one absorption enhancer. 23. The method of claim 18, wherein the non-opioid peptide NOP agonist is selected from the group consisting of N/OFQ, truncated N/OFQ analogs, N/OFQ agonist peptides and NOP agonist hexapeptides. 24. The method of claim 23, wherein the non-opioid peptide NOP agonist is a truncated N/OFQ analog. 25. The method of claim 1, wherein the non-opioid peptide NOP agonist is N/OFQ and the unit dose of the N/OFQ administered is about 0.2 mg to about 5000 mg. 26. The method of claim 1, wherein the administration results in reduction of a pain rating on the VAS of 30% or more.

Details for Patent 9,238,053

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2029-07-27